2Seventy Bio Net Worth
2Seventy Bio Net Worth Breakdown | TSVT |
2Seventy Bio Net Worth Analysis
2Seventy Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including 2Seventy Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of 2Seventy Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform 2Seventy Bio's net worth analysis. One common approach is to calculate 2Seventy Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares 2Seventy Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing 2Seventy Bio's net worth. This approach calculates the present value of 2Seventy Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of 2Seventy Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate 2Seventy Bio's net worth. This involves comparing 2Seventy Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into 2Seventy Bio's net worth relative to its peers.
Enterprise Value |
|
To determine if 2Seventy Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding 2Seventy Bio's net worth research are outlined below:
| 2Seventy Bio generated a negative expected return over the last 90 days | |
| 2Seventy Bio has high historical volatility and very poor performance | |
| 2Seventy Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 100.39 M. Net Loss for the year was (217.57 M) with loss before overhead, payroll, taxes, and interest of (183.46 M). | |
| 2Seventy Bio currently holds about 357.93 M in cash with (166.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Insider Sell Marcela Maus Sells 3,900 Shares of 2seventy bio Inc |
2Seventy Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in 2Seventy Bio. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to 2Seventy Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know 2Seventy Bio's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as 2Seventy Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading 2Seventy Bio backward and forwards among themselves. 2Seventy Bio's institutional investor refers to the entity that pools money to purchase 2Seventy Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.2 M | State Street Corp | 2024-06-30 | 1 M | Eversept Partners, Llc | 2024-09-30 | 998.1 K | Cowen And Company, Llc | 2024-06-30 | 800 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 667 K | Dafna Capital Management Llc | 2024-09-30 | 630 K | Bank Of America Corp | 2024-06-30 | 606.8 K | Healthcare Of Ontario Pension Plan Trust Fund | 2024-09-30 | 590 K | Jpmorgan Chase & Co | 2024-06-30 | 532.4 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 6.5 M | Kynam Capital Management, Lp | 2024-09-30 | 6 M |
Follow 2Seventy Bio's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 193.46 M.Market Cap |
|
Project 2Seventy Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.39) | (0.41) | |
| Return On Capital Employed | (0.43) | (0.45) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (0.85) | (0.89) |
When accessing 2Seventy Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures 2Seventy Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of 2Seventy Bio's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in 2Seventy Bio's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of 2Seventy Bio. Check 2Seventy Bio's Beneish M Score to see the likelihood of 2Seventy Bio's management manipulating its earnings.
Evaluate 2Seventy Bio's management efficiency
2Seventy Bio has return on total asset (ROA) of (0.1902) % which means that it has lost $0.1902 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5189) %, meaning that it created substantial loss on money invested by shareholders. 2Seventy Bio's management efficiency ratios could be used to measure how well 2Seventy Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.41 in 2024. Return On Capital Employed is likely to drop to -0.45 in 2024. At this time, 2Seventy Bio's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 574.1 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 2.3 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.18 | 5.48 | |
| Tangible Book Value Per Share | 5.05 | 4.94 | |
| Enterprise Value Over EBITDA | (1.90) | (1.99) | |
| Price Book Value Ratio | 0.82 | 0.78 | |
| Enterprise Value Multiple | (1.90) | (1.99) | |
| Price Fair Value | 0.82 | 0.78 | |
| Enterprise Value | 662.3 M | 640 M |
The leadership approach at 2Seventy Bio's fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Enterprise Value Revenue 5.4473 | Revenue 45.6 M | Quarterly Revenue Growth 0.125 | Revenue Per Share 0.878 | Return On Equity (0.52) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific 2Seventy Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on 2Seventy Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases 2Seventy Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
2Seventy Bio Corporate Filings
F4 | 20th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 6th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 8th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
2Seventy Bio Earnings per Share Projection vs Actual
2Seventy Bio Corporate Management
| Teresa JD | General VP | Profile | |
| Susan AbuAbsi | Chief Officer | Profile | |
| DPHIL Phil | Chief Officer | Profile | |
| Anna TruppelHartmann | Chief Officer | Profile | |
| Victoria Eatwell | Chief Officer | Profile | |
| Steven Shamah | Head Research | Profile |
Additional Tools for 2Seventy Stock Analysis
When running 2Seventy Bio's price analysis, check to measure 2Seventy Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 2Seventy Bio is operating at the current time. Most of 2Seventy Bio's value examination focuses on studying past and present price action to predict the probability of 2Seventy Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 2Seventy Bio's price. Additionally, you may evaluate how the addition of 2Seventy Bio to your portfolios can decrease your overall portfolio volatility.